Amsterdam Molecular Therapeutics (AMT) Announces Results of Extraordinary General Meeting
Published: Apr 02, 2012
AMSTERDAM, The Netherlands, March 30, 2012 /PRNewswire/ --
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced that the Extraordinary General Meeting (EGM) of shareholders was held in Amsterdam, the Netherlands, today in accordance with the EGM Notice of February 17, 2012. At the EGM, shareholders approved all the resolutions proposed for the substantial corporate restructuring and financing transaction, which will result in the assets and certain liabilities being acquired by a newly formed private company, uniQure BV, and the AMT legal entity being liquidated.
The shareholders in uniQure previously included a condition to the transaction that meant an additional 1.0 million of investment was to be secured by AMT prior to completion. This condition has been waived. Completion of the uniQure transaction is expected to occur in early April 2012. Further details on timing on the uniQure transaction are set out on the company's website.
The resolutions put to the EGM convened in accordance with the Notice were passed by a majority in excess of 99 percent. The detailed voting information and results pursuant to Section 2:120 paragraph 5 of the Dutch Civil Code will be posted on the website http://www.amtbiopharma.com.
About Amsterdam Molecular Therapeutics
AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry. The assets of AMT are subject to a proposed acquisition by uniQure BV. AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.
uniQure BV is a private company created specifically to acquire specific assets and liabilities of Amsterdam Molecular Therapeutics (AMT). The company is funded by Forbion Capital Partners, an existing investor in AMT. uniQure will act as the new holding company for the gene therapy business currently carried out by AMT.
Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law.
SOURCE Amsterdam Molecular Therapeutics (AMT) B.V